eXoZymes (EXOZ) Competitors $12.20 -0.48 (-3.79%) As of 01:42 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock EXOZ vs. EOLS, BNTC, AMRN, AURA, YMAB, DSGN, KMDA, IVVD, LBRX, and REPLShould you be buying eXoZymes stock or one of its competitors? The main competitors of eXoZymes include Evolus (EOLS), Benitec Biopharma (BNTC), Amarin (AMRN), Aura Biosciences (AURA), Y-mAbs Therapeutics (YMAB), Design Therapeutics (DSGN), Kamada (KMDA), Invivyd (IVVD), LB Pharmaceuticals (LBRX), and Replimune Group (REPL). These companies are all part of the "pharmaceutical products" industry. eXoZymes vs. Its Competitors Evolus Benitec Biopharma Amarin Aura Biosciences Y-mAbs Therapeutics Design Therapeutics Kamada Invivyd LB Pharmaceuticals Replimune Group Evolus (NASDAQ:EOLS) and eXoZymes (NASDAQ:EXOZ) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings. Do analysts prefer EOLS or EXOZ? Evolus currently has a consensus price target of $21.25, suggesting a potential upside of 217.64%. Given Evolus' stronger consensus rating and higher possible upside, equities research analysts clearly believe Evolus is more favorable than eXoZymes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evolus 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has preferable earnings & valuation, EOLS or EXOZ? eXoZymes has lower revenue, but higher earnings than Evolus. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvolus$266.27M1.63-$50.42M-$0.98-6.83eXoZymes$70K1,462.26-$5.86MN/AN/A Is EOLS or EXOZ more profitable? eXoZymes has a net margin of 0.00% compared to Evolus' net margin of -22.31%. eXoZymes' return on equity of -134.50% beat Evolus' return on equity.Company Net Margins Return on Equity Return on Assets Evolus-22.31% -759.04% -24.63% eXoZymes N/A -134.50%-81.63% Do institutionals & insiders believe in EOLS or EXOZ? 90.7% of Evolus shares are held by institutional investors. 6.1% of Evolus shares are held by company insiders. Comparatively, 72.4% of eXoZymes shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media prefer EOLS or EXOZ? In the previous week, Evolus had 2 more articles in the media than eXoZymes. MarketBeat recorded 2 mentions for Evolus and 0 mentions for eXoZymes. Evolus' average media sentiment score of 0.30 beat eXoZymes' score of 0.00 indicating that Evolus is being referred to more favorably in the media. Company Overall Sentiment Evolus Neutral eXoZymes Neutral SummaryEvolus beats eXoZymes on 8 of the 13 factors compared between the two stocks. Get eXoZymes News Delivered to You Automatically Sign up to receive the latest news and ratings for EXOZ and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EXOZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXOZ vs. The Competition Export to ExcelMetriceXoZymesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$102.36M$3.48B$6.18B$10.69BDividend YieldN/A2.27%5.70%4.84%P/E RatioN/A23.3929.4727.36Price / Sales1,462.26482.23588.68132.91Price / CashN/A45.2825.8230.35Price / Book9.7610.6112.526.69Net Income-$5.86M-$52.56M$3.32B$276.59M7 Day Performance-6.08%4.94%2.43%0.97%1 Month Performance-15.69%16.10%8.79%3.95%1 Year PerformanceN/A14.51%62.12%36.41% eXoZymes Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXOZeXoZymesN/A$12.20-3.8%N/AN/A$102.36M$70K0.0029EOLSEvolus3.9673 of 5 stars$6.30-4.7%$21.25+237.3%-61.5%$427.57M$266.27M-6.43170BNTCBenitec Biopharma1.265 of 5 stars$15.70-1.3%$24.80+58.0%+36.3%$417.38M$80K-10.6820AMRNAmarin0.484 of 5 stars$20.07+0.5%$12.00-40.2%+69.3%$413.04M$228.61M-5.47360AURAAura Biosciences2.0033 of 5 stars$6.19-2.5%$22.00+255.4%-51.7%$394.46MN/A-3.1650YMABY-mAbs Therapeutics1.3656 of 5 stars$8.61flat$9.62+11.8%N/A$391.24M$87.68M-17.22150DSGNDesign Therapeutics0.1248 of 5 stars$6.17-8.0%N/A+2.6%$382.12MN/A-5.5140KMDAKamada4.5068 of 5 stars$6.75+2.3%$13.00+92.6%+24.1%$379.53M$160.95M19.85360Positive NewsIVVDInvivyd3.8786 of 5 stars$1.75flat$5.14+193.6%+80.0%$375.22M$25.38M-1.90100LBRXLB PharmaceuticalsN/A$16.40-0.7%$30.50+86.0%N/A$370.76MN/A0.0016Quiet Period ExpirationREPLReplimune Group4.2199 of 5 stars$4.67-1.5%$6.50+39.2%-61.0%$369.98MN/A-1.44210Trending NewsAnalyst UpgradeGap Up Related Companies and Tools Related Companies Evolus Competitors Benitec Biopharma Competitors Amarin Competitors Aura Biosciences Competitors Y-mAbs Therapeutics Competitors Design Therapeutics Competitors Kamada Competitors Invivyd Competitors LB Pharmaceuticals Competitors Replimune Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EXOZ) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredThis dark force is about to change everythingSomething unusual is unfolding inside the Republican Party — from Marjorie Taylor Greene breaking ranks to Ted...Porter & Company | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eXoZymes Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share eXoZymes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
